MSTN and neoplasm: In fact, experimental blockade of myostatin/activin (such as with ACVR2B receptors traps) in tumor-bearing mice not only increases muscle mass but also prevents cachexia-associated bone loss, reinforcing the myostatin link in muscle–bone pathology [277].